Vision

Every year, European and US pharmaceutical companies spend hundred billions of dollars to get their new medical devices and medicines approved in Europe and USA. Many small and middle size pharmaceutical companies in Europe and in United States have no knowledge, resources and strategies for their medical and pharmaceutical products to be sold in Asia and China.

At the same time, there are hundred millions of people in Asia and China with excess buying powers but with very limited access to the new medical and pharmaceutical products approved in Europe and United States due to international regulatory barriers.

Medipharma licensing Limited is to bridge the very strong market demands in Asia and China with the newly approved medical and pharmaceutical products from small size and middle size pharmaceutical companies in Europe and United States.

Due to different European and US pharmaceutical companies’ products, to expand their product lines in Asia and in China can take different forms through licensing or alliance management.

One way is to register an overseas medical or a pharmaceutical product in Asia countries or in China, then use an import/export mechanism to reach the market in Asia and China with sales networks in the host countries. In general, Asia and China are weak places for pharmaceutical R&D as compared to their Western counter parts. This is due to the R&D talents, local pharmaceutical companies R & D funding structures and capital market financing mechanisms. Even with top pharmaceutical companies in this region, they often with very limited pipeline to meet a fast economic market growth.

There are other alliance management mechanisms to leverage advanced medical and pharmaceutical products with huge market potentials in Asia and China.

Medipharma Licensing Limited is here to help address such imbalance by bridging market demand with the advanced medical and pharmeautical products from Europe and United States.